Clinical Trials Directory
We are doing this study to collect data and samples to store them for future research. We hope the data and samples will lead to improved treatment of patients who are seriously ill or have been injured.
This is a biosample collection study for people in the Surgical Critical Initiative Tissue and Data Acquisition Study If you join this study, you will: - Have blood drawn (an extra 2 teaspoons) at time of your injury or surgery, on Days 1, 3 and 7 after your injury or surgery, and weekly while you are in the hospital. We may also collect fluid or tissue from your wound and pictures of it We will also collect blood near time of surgery or if you get worse. We will also ask to use data collected under TDAP for analyses.
We are doing this to see the effects of giving long-term red blood cell exchange transfusion to patients with sickle cell disease (SCD). We want to know if exchange blood transfusion may help with serious complications of SCD or reduce the chances of a new, serious problem happening.
We are doing this study to find the most effective, safe dose of an experimental drug called SGR-1505 (the study drug). We want to know how well this study drug specifically targets a protein related to your B-cell cancer.
We are doing this study to determine whether specialty palliative care or primary palliative care is the best way to improve the quality of life and experience of patients and their caregivers.
The purpose of this research study is to determine whether data from mobile health technologies (such as smartwatches and smartphones) can be used to assess risk of prediabetes and type 2 diabetes. Using data from smartphones and smartwatches, we may be able to develop a noninvasive procedure for identifying patients who are at risk and should be tested for diabetes. Participants can earn up to $50. For more information about who can be in this study, please contact the study team at diabeteswatch2@duke.edu.
If you join this study, you will first go through a screening period to make sure you qualify. If you qualify, you will be placed into one of two groups by chance, like drawing names from a hat. Group 1 will get one dose of a medicine called rademikibart. Group 2 will get one dose of a placebo, which looks like the medicine but does not have any active drug. The study will include about nine visits over a period of eight to thirty‑four weeks.
We are testing a new type of electrode and a special computer system that can read signals from the skin. The person in the study will wear these new electrodes on their feet.